Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Merck pauses Gardasil shipments to China, hitting its 2025 outlook
06:32am, Tuesday, 04'th Feb 2025
Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong fou
Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
06:30am, Tuesday, 04'th Feb 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results.
The Dow Jones Industrials Are Winning 2025: 4 Highest-Yielding Dogs of the Dow Are Steals
04:12pm, Monday, 03'rd Feb 2025
The Dow Jones industrial average (DJIA) is a price-weighted average of 30 blue-chip U.S.
Gardasil Worries Loom as Merck Reports Earnings
03:12pm, Monday, 03'rd Feb 2025
Merck shares are down more than 20% over the past 12 months after trouble with sales of its Gardasil vaccine in China
Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?
01:49pm, Monday, 03'rd Feb 2025
Merck & Co Inc MRK and Pfizer Inc PFE are duking it out for investor attention with fourth-quarter earnings being reported on Tuesday.
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
12:25pm, Monday, 03'rd Feb 2025
The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, Capvaxive.
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?
12:20pm, Monday, 03'rd Feb 2025
Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.
5 Relatively Secure And Cheap Dividend Stocks, Yields Upto 8% (February 2025)
09:00am, Saturday, 01'st Feb 2025
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
03:31pm, Friday, 31'st Jan 2025
Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program are key focus areas for potential healthcare reforms.
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
02:15pm, Friday, 31'st Jan 2025
MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's overall clinical program data.
Unveiling Merck (MRK) Q4 Outlook: Wall Street Estimates for Key Metrics
10:21am, Friday, 31'st Jan 2025
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quart
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
10:06am, Thursday, 30'th Jan 2025
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck to stop lung condition drug study early due to strong efficacy data
06:48am, Thursday, 30'th Jan 2025
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
06:45am, Thursday, 30'th Jan 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis.
